Is Pieris Pharmaceuticals, Inc. overvalued or undervalued?

As of 15 May 2025, Pieris Pharmaceuticals, Inc. has moved from a valuation grade of risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently overvalued, with a price-to-book ratio of 5.13 and a negative return on equity (ROE) of -30.71%. Additionally, the EV to EBITDA ratio stands at -12.36, reflecting ongoing losses and a lack of profitability.
In comparison to its peers, Pieris Pharmaceuticals shows a stark contrast, as companies like Elevation Oncology, Inc. and Enlivex Therapeutics Ltd. also do not qualify but have less severe valuations with EV to EBITDA ratios of 0.5869 and -0.2828, respectively. The company's stock performance has been volatile, with a year-to-date return of 87.83%, which, while impressive, is overshadowed by a 3-year decline of -84.93% compared to the S&P 500's 58.74% return in the same period. This further emphasizes the overvaluation of Pieris Pharmaceuticals in the current market context.